Understanding Melanotan II and Its Mechanisms

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Overview of the Melanocortin System

The melanocortin system is composed of five G-protein coupled receptors (MC1R–MC5R), which respond to naturally occurring agonists such as alpha-, beta-, and gamma-melanocyte stimulating hormones (MSH), as well as adrenocorticotropic hormone (ACTH). Endogenous antagonists include agouti and agouti-related protein (AGRP).

These receptors are expressed in a tissue-specific manner and demonstrate variable affinity for the melanocortin peptides. Collectively, they influence diverse physiological processes including pigmentation, lipid metabolism, appetite regulation, thermogenesis, sexual behavior, immune response, and memory.

Animal models and genetic research have highlighted the pivotal role of melanocortins in regulating pigmentation, energy balance, and inflammatory processes. Consequently, melanocortin receptors are now being investigated as therapeutic targets for conditions such as obesity, inflammation, and glucocorticoid deficiency.

What is Melanotan II?

Melanotan II (MTII) is a synthetic analog of alpha-MSH. Structurally, it is a truncated derivative of Melanotan I (afamelanotide) with a cyclic lactam modification, which improves blood–brain barrier penetration and extends its half-life.

MTII acts as a non-selective agonist at MC1R, MC3R, MC4R, and MC5R receptors. Initially developed for its ability to stimulate pigmentation, researchers also observed enhanced libido and potential metabolic benefits. Through MC1R, it drives melanogenesis, while MC3R and MC4R are associated with appetite regulation, sexual function, and energy expenditure.

Documented Research Benefits

• Stimulates melanin production and enhances skin photoprotection
  
• Improves sexual desire and erectile function
  
• Modulates immune response by enhancing T regulatory cell activity and restoring Th1/Th17 balance
  
• Regulates appetite and supports lipid and glucose metabolism
  
• Exerts neuroprotective effects and reduces neuroinflammation
  
• Influences dopaminergic signaling pathways 

Areas of Application

• Induction of skin tanning and protection against phototoxicity
  
• Management of erythropoietic protoporphyria
  
• Metabolic regulation including appetite suppression and lipolysis
  
• Modulation of immune dysregulation and autoimmune disorders
  
• Adjunctive therapy for sexual dysfunction
• Investigational use in addiction management (opioids, alcohol, cocaine)
  

Role in Pigment Production

Melanogenesis is the process by which melanocytes produce melanin within melanosomes. Melanin not only defines skin, hair, and eye color but also protects against ultraviolet radiation (UVR).

MTII stimulates MC1R, initiating a cascade:

1. Activation of adenylate cyclase and elevation of cyclic AMP
   
2. cAMP activation of protein kinase A (PKA)
   
3. Phosphorylation of CREB (cAMP response element binding protein)
   
4. CREB-mediated expression of MITF (microphthalmia-associated transcription factor)
   
5. Increased synthesis of melanogenic enzymes
   

The outcome is enhanced melanin production, leading to darker pigmentation and greater resistance to UV-induced damage.

Sexual Health Implications

Central melanocortin receptors are implicated in both male erectile function and female sexual behavior. MC4R and MC3R activation stimulates sexual responses in animal models and human studies.

Clinical research on bremelanotide (PT-141), a selective MC4R agonist, supports its role in female sexual arousal and male erectile dysfunction. MTII, as a broader receptor agonist, influences dopamine signaling and reward pathways, thereby contributing to sexual desire and arousal.

Immune and Anti-inflammatory Actions

Chronic inflammation contributes to autoimmune and degenerative conditions. Melanocortin receptor activation has demonstrated significant anti-inflammatory effects, including:

• Downregulation of proinflammatory cytokines (TNF-α, IL-1, IL-6, IL-8)
  
• Reduced nitric oxide and inducible nitric oxide synthase expression
  
• Enhanced IL-10 production
  
• Inhibition of NF-κB signaling
  
• Prevention of immune cell infiltration into tissues, including the central nervous system
  

These effects make MTII a candidate for managing autoimmune disorders and neuroinflammatory conditions such as multiple sclerosis.

Read more about: glutathione 

Metabolic and Weight Regulation

MTII has been shown to suppress appetite and increase energy expenditure through MC4R activation. Studies suggest that MC4R dysfunction contributes to obesity, and synthetic agonists like MTII may counteract this by reducing food intake while enhancing thermogenesis.

In addition, MTII may improve lipid and glucose profiles, further supporting its role in metabolic health.

Neuroprotection and Brain Health

Melanocortin receptors within the nervous system contribute to neuroprotection. MTII has been associated with:

• Reduced neuroinflammation
  
• Promotion of brain-derived neurotrophic factor (BDNF) expression
  
• Enhanced neuronal recovery following injury
  
• Potential therapeutic effects in neurodegenerative diseases such as Alzheimer’s 

Additionally, MTII’s influence on dopaminergic pathways suggests utility in mood regulation and social bonding.

Addiction and Substance Use Disorders

The melanocortin system modulates responses to addictive substances. MTII has been shown to:

• Reduce ethanol consumption by enhancing the effects of naltrexone
  
• Mitigate tolerance to opioids
  
• Influence dopamine release in brain reward pathways 

These findings highlight potential use as an adjunctive therapy in managing substance use disorders.

Cardiovascular Effects

Melanocortins impact cardiovascular physiology through sympathetic nervous system activation and vascular protection. MTII and related agonists have been reported to:

• Increase blood pressure and heart rate via MC4R
  
• Reduce reperfusion injury in cardiac tissue
  
• Promote endothelial function through anti-inflammatory pathways

REFERENCES

1. Cai M, Mayorov AV, Ying J, Stankova M, Trivedi D, Cabello C, Hruby VJ. Design of novel melanotropin agonists and antagonists with high potency and selectivity for human melanocortin receptors. Peptides. 2005 Aug;26(8):1481-5. doi: 10.1016/j.peptides.2005.03.020. PMID: 15876475.
2. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9. doi: 10.1038/sj.ijir.3900582. PMID: 11035391.
3. Shadiack, A., Althof, S. Preclinical effects of melanocortins in male sexual dysfunction. Int J Impot Res 20 (Suppl 1), S11–S16 (2008). https://doi.org/10.1038/ijir.2008.17
4. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10201-4. doi: 10.1073/pnas.0400491101. Epub 2004 Jun 28. PMID: 15226502; PMCID: PMC454387.
5. Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res. 2005 Apr 1;571(1-2):133-52. doi: 10.1016/j.mrfmmm.2004.09.014. Epub 2005 Jan 26. PMID: 15748644.
6. Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X, Drisko J, Cashen D, Sebhat I, Patchett AA, Figueroa DJ, DiLella AG, Connolly BM, Weinberg DH, Tan CP, Palyha OC, Pong SS, MacNeil T, Rosenblum C, Vongs A, Tang R, Yu H, Sailer AW, Fong TM, Huang C, Tota MR, Chang RS, Stearns R, Tamvakopoulos C, Christ G, Drazen DL, Spar BD, Nelson RJ, MacIntyre DE. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11381-6. doi: 10.1073/pnas.172378699. Epub 2002 Aug 9. PMID: 12172010; PMCID: PMC123265.

Product available for research use only: